ICON Public Limited (NASDAQ:ICLR) Given Average Recommendation of “Buy” by Analysts

Shares of ICON Public Limited (NASDAQ:ICLR) have received an average rating of “Buy” from the twelve brokerages that are currently covering the firm, Marketbeat.com reports. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $351.60.

ICLR has been the subject of a number of analyst reports. StockNews.com lowered shares of ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. Barclays reduced their target price on shares of ICON Public from $355.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Truist Financial reissued a “buy” rating and set a $383.00 target price on shares of ICON Public in a research note on Wednesday, September 11th. The Goldman Sachs Group initiated coverage on shares of ICON Public in a research report on Thursday, June 6th. They set a “buy” rating and a $370.00 price target on the stock. Finally, Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th.

Institutional Trading of ICON Public

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC raised its holdings in shares of ICON Public by 39.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after purchasing an additional 111 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of ICON Public in the 2nd quarter worth approximately $54,000. Kornitzer Capital Management Inc. KS raised its holdings in shares of ICON Public by 15.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock worth $30,016,000 after purchasing an additional 13,163 shares in the last quarter. Crestwood Advisors Group LLC bought a new stake in shares of ICON Public in the 2nd quarter worth approximately $288,000. Finally, WR Wealth Planners LLC raised its holdings in shares of ICON Public by 4.7% in the 2nd quarter. WR Wealth Planners LLC now owns 2,359 shares of the medical research company’s stock worth $739,000 after purchasing an additional 105 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

ICON Public Trading Up 0.6 %

NASDAQ ICLR opened at $287.31 on Tuesday. ICON Public has a one year low of $221.20 and a one year high of $347.72. The company has a 50-day simple moving average of $311.35 and a 200-day simple moving average of $316.00. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31. The firm has a market capitalization of $23.70 billion, a PE ratio of 34.95, a price-to-earnings-growth ratio of 1.32 and a beta of 1.22.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.68 by $0.07. The firm had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.14 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. ICON Public’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.96 EPS. On average, equities analysts forecast that ICON Public will post 14.54 earnings per share for the current year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.